J&J: approval of Balversa in bladder cancer in the EU
(CercleFinance.com) - Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, announced that the European Commission has approved Balversa (erdafitinib) for the daily oral treatment of metastatic or unresectable urothelial carcinoma in adults.
Bladder cancer is widespread in Europe, with a significant increase in cases in recent years.
Erdafitinib is a targeted therapy that has shown a significant improvement in progression-free and overall survival compared to chemotherapy, according to the results of a Phase 3 study.
The approval highlights the importance of FGFR testing to personalize treatment, and the need for a multidisciplinary approach to optimize care.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Bladder cancer is widespread in Europe, with a significant increase in cases in recent years.
Erdafitinib is a targeted therapy that has shown a significant improvement in progression-free and overall survival compared to chemotherapy, according to the results of a Phase 3 study.
The approval highlights the importance of FGFR testing to personalize treatment, and the need for a multidisciplinary approach to optimize care.
Copyright (c) 2024 CercleFinance.com. All rights reserved.